Remedee Labs’ Solution becomes the first CE marked medical device (class IIa) approved for the treatment of fibromyalgia in Europe Read the press release.
Contact us

Remedee Labs announces positive results from its clinical trial on osteoarthritis.

Partager cet article

Remedee Labs, a French startup that specializes in non-pharmaceutical treatments for chronic pain, is announcing the highly anticipated results of its clinical study assessing the effectiveness of its millimeter waves neuromodulation device for osteoarthritis patients today.

The initial results showed a significant decrease in pain and an improvement in sleep quality and overall quality of life among patients who used the device.

A clinical study confirms the effectiveness of endorphin stimulation in relieving osteoarthritis pain.

This randomized crossover study was conducted by the Grenoble Alpes University Hospital on 60 volunteers with peripheral osteoarthritis (ankle, knee, hip, shoulder, elbow, finger).

Remedee Labs’ innovative non-invasive technology, which was tested in this clinical trial, is based on a unique millimeter waves neuromodulation technique that stimulates the release of endorphins, the body’s natural painkillers, to improve users’ quality of life.

—> Learn more about millimeter waves neuromodulation  

“The study results showed that regular use of the wristband (1 to 3 times per day) for 3 months significantly reduced pain (VAS) in patients with peripheral osteoarthritis. This is the first set of clinical results to demonstrate the efficacy of millimeter waves neuromodulation in the management of patients with osteoarthritis."
Docteur Laurent Grange
Dr. Laurent Grange Rheumatologist at Grenoble Alpes University Hospital
The study authors also observed an overall improvement in quality of life (EQ5D-5L) and better sleep quality (VAS) in the patients in the study. No severe side effects were observed. These results have be presented at the European Congress of Rheumatology (EULAR) in Milan on June 2nd and the full results of the trial published in a peer-reviewed journal.
“We are extremely excited to share the initial results of this clinical trial. We need new, non-pharmaceutical approaches. This non-pharmaceutical therapy is safe and easy to use, opening up new perspectives for osteoarthritis pain management thanks to its holistic impact on patients’ quality of life.”
Caroline Maindet
Dr. Caroline Maindet Pain Specialist at Grenoble Alpes University Hospital and principal investigator of the EPIKARTHROSE study
The study results confirm the effectiveness of millimeters neuromodulation in the management of patients with peripheral osteoarthritis and indicate that it has potential for other conditions that present central hypersensitization with no satisfactory solution, including fibromyalgia.
“This study is a major turning point for Remedee Labs. These clinical results validate over a decade of research and clearly prove the effectiveness of millimeter waves in the management of patients with peripheral osteoarthritis and they are entirely consistent with our real-world data generated using our ‘well-being’ solution. They also indicate our technology’s potential for other conditions that present central hypersensitization with no satisfactory solution, such as fibromyalgia.”
Dr. David CROUZIER (PhD)
Cofounder and CEO of Remedee Labs.

Based on these results, Remedee Labs plans to continue the certification process to earn medical device approval for the indication osteoarthritis and aims to begin marketing the medical device version of its solution in 2025.

About Remedee's technology

Remedee Labs has developed an innovative, comprehensive non-pharmaceutical solution based on a biopsychosocial approach that takes patients’ biological, psychological, and social factors into account. The solution combines Remedee Labs’ millimeter waves neuromodulation technology (validated by the EPIKARTHROSE study) with a personalized support program for long-term improvement in quality of life.
bracelet remedee stimulateur d'endorphines neuromodulation ondes millimétriques

1st milimeter waves neuromodulation technology

coaching

Coaching

application mobile

Remedee App

The distinctive feature of this new treatment for osteoarthritis is that it does not rely solely on the use of medication, but offers comprehensive care for patients.

The solution offers a remote support program via a dedicated coach, educational modules and methods designed by specialists, and personalized monitoring enabling the user to track his or her history and quality-of-life improvement indicators. 

About osteoathritis

Osteoarthritis is a joint disease characterized mainly by the destruction of cartilage. It is often associated with severe pain of mixed mechanical and nociplastic origin. Symptomatic osteoarthritis manifests as severe pain and/or restricted movement, which negatively affects patients’ quality of life. Osteoarthritis, including all locations, affects approximately 15% of the population.

In France, that means some 10 million people have osteoarthritis, 6 to 7 million of whom are symptomatic. There is currently no medication that can cure osteoarthritis or stop its progress. A combination of pharmaceutical and non-pharmaceutical treatments is recommended to manage patients’ pain.

Partager cet article